Folketrygdfondet Has Lowered By $21.67 Million Its Novo (NVO) Position; Umb Financial (UMBF) Has 1.45 Sentiment

June 19, 2017 - By Dolores Ford

Folketrygdfondet decreased Novo (NVO) stake by 9.2% reported in 2016Q4 SEC filing. Folketrygdfondet sold 619,091 shares as Novo (NVO)’s stock rose 15.20%. The Folketrygdfondet holds 6.11M shares with $219.13M value, down from 6.73M last quarter. Novo now has $85.94B valuation. The stock rose 1.04% or $0.45 reaching $43.65. About 660,147 shares traded. Novo Nordisk A S (ADR) (NYSE:NVO) has declined 23.93% since June 19, 2016 and is downtrending. It has underperformed by 40.63% the S&P500.

UMB Financial Corporation is a diversified financial holding company. The company has market cap of $3.60 billion. The Firm supplies banking services, institutional investment management, asset servicing and payment solutions to its clients in the United States and around the globe. It has a 21.82 P/E ratio. The Company’s divisions include Bank, which provides a range of banking services to commercial, retail, government and correspondent bank clients through the Company’s branches, call center, Internet banking and automated teller machine network; Institutional Investment Management, which provides equity and fixed income investment strategies in the intermediary and institutional markets, and Asset Servicing, which provides services to the asset management industry, supporting a range of investment products, including mutual funds, alternative investments and managed accounts.

Among 13 analysts covering Novo Nordisk (ADR) (NYSE:NVO), 4 have Buy rating, 1 Sell and 8 Hold. Therefore 31% are positive. Novo Nordisk (ADR) had 14 analyst reports since August 28, 2015 according to SRatingsIntel. Jyske Bank upgraded the stock to “Strong Buy” rating in Monday, October 19 report. As per Tuesday, September 13, the company rating was upgraded by BNP Paribas. The firm has “Neutral” rating by JP Morgan given on Friday, September 9. DNB Markets downgraded Novo Nordisk A S (ADR) (NYSE:NVO) on Monday, October 31 to “Hold” rating. As per Monday, February 8, the company rating was downgraded by UBS. The firm has “Underperform” rating given on Friday, October 28 by Bank of America. The stock has “Neutral” rating by Citigroup on Monday, October 31. The company was initiated on Friday, August 28 by Leerink Swann. The rating was upgraded by Goldman Sachs on Monday, February 15 to “Conviction Buy”. On Thursday, September 1 the stock rating was downgraded by Morgan Stanley to “Equal-Weight”.

Analysts await Novo Nordisk A S (ADR) (NYSE:NVO) to report earnings on August, 4. They expect $0.54 EPS, down 10.00% or $0.06 from last year’s $0.6 per share. NVO’s profit will be $1.06B for 20.21 P/E if the $0.54 EPS becomes a reality. After $0.58 actual EPS reported by Novo Nordisk A S (ADR) for the previous quarter, Wall Street now forecasts -6.90% negative EPS growth.

About 68,819 shares traded. UMB Financial Corp (UMBF) has risen 26.44% since June 19, 2016 and is uptrending. It has outperformed by 9.74% the S&P500.

Umb Bank N A Mo holds 16.6% of its portfolio in UMB Financial Corp for 5.85 million shares. Keeley Asset Management Corp owns 645,704 shares or 2.12% of their US portfolio. Moreover, Tributary Capital Management Llc has 1.68% invested in the company for 185,164 shares. The Illinois-based Skyline Asset Management Lp has invested 1.59% in the stock. Rice Hall James & Associates Llc, a California-based fund reported 333,473 shares.

Ratings analysis reveals 0 of UMB Financial Corporation’s analysts are positive. Out of 3 Wall Street analysts rating UMB Financial Corporation, 0 give it “Buy”, 0 “Sell” rating, while 3 recommend “Hold”. UMBF was included in 3 notes of analysts from January 6, 2017. The stock of UMB Financial Corp (NASDAQ:UMBF) has “Mkt Perform” rating given on Tuesday, January 10 by FBR Capital. Piper Jaffray downgraded the stock to “Neutral” rating in Tuesday, January 10 report. The rating was initiated by Wells Fargo on Friday, January 6 with “Market Perform”.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.



Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: